Replenish the source within

We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and regulatory T cells, causing profound immune dysfunctions in the tumor microenvironment. In line with this notion, the dual blockade of PD-1- and CTLA4-conveyed signals may exert robust therapeutic effects. Here, we discuss the mechanisms possibly underlying such a synergic interaction.

• Publication year

  2013

• Venue

  Oncoimmunology

• Publication date

  2013-08-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.4161/onci.25912PMID 24404420PMCID 3879129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

  2013cited by this paper
• Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

  2013cited by this paper
• Strength of PD-1 signaling differentially affects T-cell effector functions

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

  2010cited by this paper
• PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

  2009cited by this paper
• PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.

  2009influential reference
• Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

  2007cited by this paper
• Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

  2003cited by this paper
• GM-CSF-secreting melanoma vaccines

  2003cited by this paper

• Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed

  2022cites this paper
• Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells

  2019cites this paper
• CpG-ODN Facilitates Effective Intratracheal Immunization and Recall of Memory against Neoantigen-Expressing Alveolar Cells

  2017cites this paper
• Trial Watch: Peptide-based anticancer vaccines

  2015cites this paper
• Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches

  2015cites this paper
• Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.

  2014cites this paper
• Immunotherapy for ovarian cancer: recent advances and perspectives

  2014cites this paper
• Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond.

  2014cites this paper